Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P43026 (lipopolysaccharide)
 62,215 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Normal peritoneal macrophages from C3H/He mice could not lyse syngeneic MM46 tumor cells in co-operation with syngeneic antitumor antibody. Thus, normal macrophages could not effectively participate in the antibody-dependent macrophage-mediated tumor lysis in vitro. However, after activation in vivo by stimuli, such as lipopolysaccharide, BCG, or glycogen, macrophages could co-operate with antitumor antibody in cytolysis of target cells. In the cytolysis nonspecific activation of normal macrophages was an essential first step, followed by specific tumor lysis in the presence of an antitumor antibody (second step). Immune macrophages from resistant mice were apparently equal in functional state to activated macrophages. A two-step mechanism of tumor lysis in vitro in a syngeneic mammary tumor system is proposed.
 ...
PMID:Two-step mechanism of macrophage-mediated tumor lysis in vitro. 79 28

A low-toxic lipopolysaccharide (BP-LPS) was isolated from killed Bordetella pertussis (Tohama strain). LD50 of BP-LPS was about 0.8 mg/mouse which was about 10-fold higher than the LD50 of E. coli-LPS(80 micrograms/mouse). Toxicity measured by decrease in body weight of BP-LPS-injected mice was similarly low. BP-LPS had strong antitumor activities against various murine syngeneic tumors, and its systemic administration caused clear regression of such as MM46 mammary carcinoma and Meth A fibrosarcoma. It is noteworthy that a tolerable dosage of BP-LPS (375 micrograms/mouse) showed clear antitumor activity against MH134 hepatoma, which is known to be insusceptible to usual types of BRM including bacterial LPS. These findings suggest that BP-LPS is a promising candidate as an antitumor agent for clinical use. Biological activities of BP-LPS were examined and compared with those of toxic LPS extracted from Escherichia coli and other enterobacteria. Activation or stimulation of macrophages and lymphocytes by these LPS, including TNF induction, was found to be similar. However, activation of human or murine neutrophils, as estimated by neutrophil-adherence assay in vitro, though induced by all other toxic LPS tested, was not induced by BP-LPS. This inability of BP-LPS to activate neutrophils is assumed to be related to its low toxicity.
 ...
PMID:BRM activities of low-toxic Bordetella pertussis lipopolysaccharides. 141 7

Induction of endogenous tumor necrosis factor (TNF) by administration of Bordetella pertussis vaccine (BPV) as a triggering agent and its therapeutic effect against MM46 carcinoma were investigated in C3H/He mice. Test triggering agents were injected intravenously into mice after intravenous injection of 4-fold dilution of macrophage activating factor (MAF) or 10(4) units of murine interferon-gamma (Mu-IFN-gamma). Then sera were obtained from the mice, and their TNF activities were assayed on L-929 cells by the method of Ruff and Gifford. The triggering activity of BPV was the highest among those of conventional triggers, such as lipopolysaccharide (LPS) of Escherichia coli, and OK-432. The levels of serum TNF activity triggered by BPV (4 X 10(9) cells), LPS of E. coli (3 micrograms) and OK-432 (3 KE) were 5350, 85 and 102 units/ml, respectively. Growth of MM46, a spontaneous mammary carcinoma cell line of C3H/He was observed for 35 days after tumor inoculation and was suppressed significantly by intravenous injection of MAF and BPV (4 X 10(9) cells). On local injection of BPV (2 X 10(9) cells) into murine tumors, complete regression was observed in 67% of the mice tested with or without MAF priming on day 25 after tumor inoculation, and intratumoral TNF activity was observed even in the case of the single injection of BPV.
 ...
PMID:Endogenous tumor necrosis factor induction with Bordetella pertussis vaccine as a triggering agent and its therapeutic effect on MM46 carcinoma-bearing mice. 313 Dec 86

The antitumor effects of lentinan and bacterial lipopolysaccharide (LPS) were studied. Combined treatment with lentinan and LPS was very effective against Ehrlich carcinoma in ddY mice, and the syngeneic mammary carcinoma MM46 in C3H/He mice. Studies on the effective doses and times of administration showed that a single injection of lentinan plus LPS 12 days after subcutaneous inoculation of these tumors caused complete regression in 60 approximately 90% of the animals; complete regression of MM46 carcinoma was seen in 83% of the animals.
 ...
PMID:Combination antitumor therapy with lentinan and bacterial lipopolysaccharide against murine tumors. 674 91

The antitumor activity of TC-13, a protein-bound polysaccharide extracted from a rare actinomycetes was tested on allogeneic and syngeneic tumors in mice. In the allogeneic Ehrlich carcinoma system, TC-13 showed antitumor activity over a broad optimal dose range, when administered by various routes such as ip, iv, sc, it (intratumorally) or po, even when given before tumor inoculation. TC-13 showed synergistic antitumor effects in combination with other immunomodulators, e.g., lipopolysaccharide, lentinan and picibanil. It showed antitumor activity against syngeneic tumors, MM46 mammary carcinoma and MCS-8 and Meth A fibrosarcoma.
 ...
PMID:Antitumor effect of polysaccharide TC-13 on allogeneic and syngeneic tumors in mice. 712 13

ONO-4007 is a novel synthetic analog of lipid A subunit and has been shown to exert antitumor activities on various experimental tumors with less toxicity than lipopolysaccharide. It remains unclear, however, what biological activities of this compound are relevant to its antitumor effects. We therefore investigated the activation of macrophages by ONO-4007 in vitro and in vivo and its implication in antitumor effects, using mouse MM46 mammary tumor as an experimental model. Intravenous injection of ONO-4007 produced significant therapeutic effects on this solid tumor. ONO-4007 could stimulate glycogen-elicited peritoneal macrophages in vitro, not only to produce tumor necrosis factor (TNF), but also to exert cytocidal activities against MM46 cells in vitro. Substantial TNF production was induced in tumor tissue by i. v. injection of ONO-4007, and its successive administration to tumor-bearing mice gave tumor-infiltrating macrophages a prominent in vitro tumoricidal activity and primed them for in vitro TNF secretion. These results suggest that activation of tumor-infiltrating macrophages to a direct tumoricidal state as well as to TNF secretion in tumor tissues may be at least some of the antitumor effects of this novel lipid A analog.
 ...
PMID:Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. 816 10

A lipopolysaccharide (BP-LPS) isolated from killed Bordetella pertussis (Tohama strain) was determined to have low toxicity based on the mortality and decrease in body weight of BP-LPS-injected mice. BP-LPS, administered intradermally or intraperitoneally, clearly inhibited the growth of an MM46 murine mammary carcinoma. When compared with a toxic Escherichia coli-derived LPS, BP-LPS displayed excellent anti-tumour activity against MH134 hepatoma and Meth A fibrosarcoma. As part of a combined chemotherapy/immunotherapy regimen, BP-LPS also seemed to prolong the lifespan of mice inoculated with Lewis lung carcinoma. BP-LPS thus appears to have valuable characteristics as an anti-tumour agent.
 ...
PMID:Anti-tumour activity of low-toxicity lipopolysaccharide of Bordetella pertussis. 819 67